My watch list  

75 Current news of High-Tech Gründerfonds Management


You can refine your search further. Select from the filter options on the left to narrow down your results.

image description
€12M Series A Financing to Develop Novel Immuno-Virotherapies Against Cancer


Abalos Therapeutics announced a EUR 12 million Series A financing round establishing its operations and leadership. The Company’s objective is to develop new immuno-oncology therapeutics based on a specific arenavirus strain that preferentially infects and proliferates in cancer cells generating ...


Create blood vessels using patient’s own cells

Vacis raises capital from Brightlands Venture Partners, HTGF, LIOF and RVO


Every year, an estimated 300.000 hemodialysis patients worldwide die as they run out of medical alternatives. One of the main reasons for these deaths is failure of the vascular access site, the blood vessel where blood is removed, filtered and returned to the body during dialysis. To solve this ...


image description
€7 Million to Generate First in Class Anti-TACA Antibodies for Cancer Treatment


Tacalyx, a biotech company focused on the discovery and development of novel anti-TACA (Tumor Associated Carbohydrate Antigens) cancer therapies, announced that it has successfully secured €7 million in seed funding. The funding round involves a syndicate of leading European life science and ...


image description
Chemistry-for-Healthcare Start-up secures seed investment


Belyntic, a Berlin-based chemistry-for-healthcare startup and developer of the Peptide Easy Clean (PEC) purification technology, has completed its seed financing round amounting to €1.3 million. The funding is led by the Investitionsbank Berlin (IBB), with the High-Tech Gründerfonds (HTGF) also ...


Boehringer Ingelheim acquires swiss biotech start-up


Boehringer Ingelheim announced its acquisition of all shares of AMAL Therapeutics SA, a private Swiss biotechnology company focused on cancer immunotherapy and advancing first in class therapeutic cancer vaccines derived from its technology platform KISIMA. AMAL’s lead vaccine ATP128 is currently ...


image description
Life science start-up Pantherna Therapeutics receives 7-digit investment

“First-in-Class“ mRNA-therapeutics for vascular diseases:


Pantherna Therapeutics secures €3.5 million in a successful seed-financing round.The funds will be used to advance R&D activities and hire additional scientific staff. The Investors are the High-Tech Gründerfonds (HTGF), European Business Angel Prof. Detlev Riesner as well as the European ...


NAVAN Closes Seed Funding Round

Investors include Amgen Ventures, HTGF and Hemi Ventures


NAVAN Technologies, Inc., a privately-held biotechnology company enabling the development of next generation cell and gene therapies through its novel, non-viral NanoStraw platform, announced it had closed a seed investment round led by Amgen Ventures, High-Tech Gründerfonds (HTGF), Hemi ...


image description
Drug discovery technology start-up DyNAbind secures seed financing


DyNAbind’s Dynamic DNA-Encoded Library technology platform allows hundreds of millions of chemical structures to be simultaneously screened and optimized against a potential drug target protein. This innovation continues to be driven forward with investment from the High-Tech Gründerfonds (HTGF), ...


image description
Start-up miRdetect receives seed financing

Consortium invests seven-digit amount in serum marker for testicular cancer detection


Together with BBM and a private investor, High-Tech Gründerfonds (HTGF) is investing a seven-figure sum in the start-up company miRdetect located in Bremen, and founded in 2016. The company founders Meike Spiekermann and Dr. Nina Winter were able to convince the investors with their novel and ...


Swiss-French biotech start-up launches

ALENTIS Therapeutics raising CHF 12.5m in a Series A to develop novel therapeutics in advanced liver disease and cancer


ALENTIS Therapeutics, a Swiss-French biotech company developing novel therapeutics in advanced liver disease and cancer, announced the completion of a Series A financing of CHF 12.5million (Euro 11.1m; USD 12.5m). The Swiss venture capital firms BioMedPartners and BB Pureos Bioventures co-led the ...


Page 1 From 8
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE